Meeting
2023 ASCO Annual Meeting
Phase 1b multicenter study to evaluate CHM 1101 in patients with recurrent or progressive glioblastoma.
Authors
Jason Blair Litten
Chimeric Therapeutics, Carlton, Australia
Jason Blair Litten , Aravind Ramakrishnan , Stephanie H. Astrow , Cassandra Harrison , Alex Aliki , Behnam Badie
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT05627323
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS2086)
DOI
10.1200/JCO.2023.41.16_suppl.TPS2086
Abstract #
TPS2086
Poster Bd #
440a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumor-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392).
First Author: Behnam Badie
First Author: Hong-jiu Dai
Poster
2016 ASCO Annual Meeting
Pilot study of T cells redirected to EGFRvIII with a chimeric antigen receptor in patients with EGFRvIII+ glioblastoma.
First Author: Donald M. O'Rourke
Poster
2023 ASCO Annual Meeting
Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.
First Author: Mason Webb